cisplatin + 5-fluorouracil + pembrolizumab

This is a combination regimen consisting of three agents: - **Cisplatin** is a platinum-based chemotherapy that forms DNA crosslinks, leading to apoptosis in rapidly dividing cells. - **5-Fluorouracil (5-FU)** is an antimetabolite chemotherapeutic that inhibits thymidylate synthase, disrupting DNA synthesis and function. - **Pembrolizumab** is a humanized monoclonal antibody targeting the programmed death receptor-1 (PD-1) on T-cells. By blocking PD-1 interaction with its ligands PD-L1 and PD-L2, pembrolizumab enhances immune-mediated tumor cell killing. This combination leverages both cytotoxic chemotherapy (cisplatin + 5-FU) and immunotherapy (pembrolizumab), aiming for synergistic anti-tumor effects. It has been studied or used in various advanced solid tumors, including head and neck squamous cell carcinoma, esophageal cancer, cervical cancer, gastric/gastroesophageal junction adenocarcinoma (especially HER2-positive cases), among others[6][7][9]. The specific indications may vary based on regulatory approvals for each component in combination regimens.

Other names

cisplatin and 5-fluorouracil and pembrolizumabcisplatin/5-FU/pembrolizumab